It's worth noting that the top diseases for ontogenesis with our information set unites epidemiology, market potential and metric scientific feasibility.
The basic idea is that desegregated data sets cover 20K+ diseases, Unmet needs, market sizing, butt biology and the for portfolio optimisation.
Data-driven disease selection that wins.
See Data Package DocumentationPrevalence, incidence, orphan status, quality-adjusted life years.
Looking at this, the global epidemiology with segmentation by geezerhood, geographics and genetic subtypes names universes of high-press patients.
Explore Epidemiology DataPeak sales forecasts, payer insights, HCP surveys included.
A central concept is that literal data on prices, quittance events and entry roadblocks create overall economical lucrativeness scores.
View Market AnalyticsDruggable targets per disease. Genetic validation strength.
Something to keep in mind is that the target mob, genetic intensity, and availability of biomarkers rank diseases by the probability of biological ontogeny.
Learn About Feasibility Scores